Snehal Patel Acquires 1,800 Shares of Greenwich LifeSciences (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel bought 1,800 shares of Greenwich LifeSciences stock in a transaction on Tuesday, January 13th. The stock was acquired at an average price of $29.83 per share, with a total value of $53,694.00. Following the completion of the purchase, the chief executive officer directly owned 5,604,102 shares of the company’s stock, valued at approximately $167,170,362.66. The trade was a 0.03% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Snehal Patel also recently made the following trade(s):

• On Monday, January 12th, Snehal Patel purchased 2,900 shares of Greenwich LifeSciences stock. The shares were acquired at an average price of $27.54 per share, for a total transaction of $79,866.00.
• On Wednesday, December 31st, Snehal Patel purchased 4,300 shares of Greenwich LifeSciences stock. The shares were acquired at an average price of $21.36 per share, for a total transaction of $91,848.00.
• On Tuesday, December 30th, Snehal Patel acquired 2,900 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $21.73 per share, with a total value of $63,017.00.
• On Thursday, December 18th, Snehal Patel acquired 4,100 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $12.62 per share, with a total value of $51,742.00.
• On Tuesday, November 25th, Snehal Patel bought 4,600 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $8.37 per share, for a total transaction of $38,502.00.
• On Friday, November 7th, Snehal Patel bought 10,600 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $8.43 per share, for a total transaction of $89,358.00.
• On Friday, October 31st, Snehal Patel purchased 2,300 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $9.26 per share, with a total value of $21,298.00.

Greenwich LifeSciences Stock Performance

GLSI opened at $24.88 on Friday. The company has a market cap of $344.59 million, a PE ratio of -17.04 and a beta of 1.47. The stock has a 50-day moving average of $14.36 and a 200-day moving average of $12.05. Greenwich LifeSciences, Inc. has a 52-week low of $7.78 and a 52-week high of $32.91.

Greenwich LifeSciences (NASDAQ:GLSI) last posted its earnings results on Friday, November 14th. The company reported ($0.30) earnings per share for the quarter, hitting the consensus estimate of ($0.30). On average, research analysts predict that Greenwich LifeSciences, Inc. will post -0.8 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Wall Street Zen raised shares of Greenwich LifeSciences from a “sell” rating to a “hold” rating in a report on Saturday, December 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Greenwich LifeSciences in a report on Monday, December 29th. Finally, HC Wainwright lifted their price objective on Greenwich LifeSciences from $39.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, December 30th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Greenwich LifeSciences presently has a consensus rating of “Hold” and an average price target of $47.50.

Institutional Trading of Greenwich LifeSciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP acquired a new position in shares of Greenwich LifeSciences during the 2nd quarter worth about $509,000. Strs Ohio acquired a new position in Greenwich LifeSciences during the first quarter worth approximately $177,000. Vanguard Group Inc. lifted its position in shares of Greenwich LifeSciences by 4.9% in the third quarter. Vanguard Group Inc. now owns 282,181 shares of the company’s stock valued at $2,808,000 after buying an additional 13,179 shares during the last quarter. Citadel Advisors LLC lifted its position in shares of Greenwich LifeSciences by 52.1% in the third quarter. Citadel Advisors LLC now owns 20,942 shares of the company’s stock valued at $208,000 after buying an additional 7,174 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in shares of Greenwich LifeSciences by 48.7% during the 1st quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock worth $92,000 after acquiring an additional 3,168 shares during the period. Institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.